KNect365 is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Probiodrug CEO outlines Phase IIb plans for potential Alzheimer’s treatments

On the back of biomarker data that indicates that its approach to targeting pyroglutamate-Abeta is a promising therapeutic strategy to fight Alzheimer’s disease, Probiodrug is now ramping up plans to run Phase IIb trials in the US and the EU. Speaking at the 2018 Biotech Showcase, Probiodrug co-founder and CEO Konrad Glund explained to Scrip the implications of previous results with its small molecule and monoclonal antibody approaches and described the company’s strategy for moving the programs forward.

Get the latest news as it happens.